Global Clavulanic Acid Series API Market Research Report 2024

Publication ID:

PB510243624

Publication Date:

October 21, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Clavulanic Acid Series API refers to active pharmaceutical ingredients (APIs) that include clavulanic acid and its derivatives. Clavulanic acid is a 尾-lactam compound used primarily as a 尾-lactamase inhibitor. It is often combined with penicillin antibiotics (like amoxicillin) to enhance their effectiveness against bacteria that produce 尾-lactamase enzymes, which can render these antibiotics ineffective.
The global Clavulanic Acid Series API market was valued at US$ 374 million in 2023 and is anticipated to reach US$ 623 million by 2030, witnessing a CAGR of 6.5% during the forecast period 2024-2030.
North American market for Clavulanic Acid Series API is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Clavulanic Acid Series API is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Clavulanic Acid Series API include Wichita, GSK, Lek Pharmaceuticals (Sandoz), CKD Bio Corporation, Zhuhai United Pharmaceutical, Shandong New Era Pharmaceutical, Sichuan Ren An Pharmaceutical, Fermic, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Clavulanic Acid Series API, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Clavulanic Acid Series API.
The Clavulanic Acid Series API market size, estimations, and forecasts are provided in terms of sales volume (Tons) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Clavulanic Acid Series API market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Clavulanic Acid Series API manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Wichita
GSK
Lek Pharmaceuticals (Sandoz)
CKD Bio Corporation
Zhuhai United Pharmaceutical
Shandong New Era Pharmaceutical
Sichuan Ren An Pharmaceutical
Fermic
Segment by Type
Potassium Clavulanate
Amoxicillin and Potassium Clavulanate
Clavulanate Potassium with Avicel
Clavulanate Potassium with Silicon Dioxide
Segment by Application
Oral Medications
Injectable Medications
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Clavulanic Acid Series API manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Clavulanic Acid Series API in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.鈥�

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Clavulanic Acid Series API Market Overview
1.1 Product Definition
1.2 Clavulanic Acid Series API by Type
1.2.1 Global Clavulanic Acid Series API Market Value Comparison by Type (2024-2030)
1.2.2 Potassium Clavulanate
1.2.3 Amoxicillin and Potassium Clavulanate
1.2.4 Clavulanate Potassium with Avicel
1.2.5 Clavulanate Potassium with Silicon Dioxide
1.3 Clavulanic Acid Series API by Application
1.3.1 Global Clavulanic Acid Series API Market Value by Application (2024-2030)
1.3.2 Oral Medications
1.3.3 Injectable Medications
1.4 Global Clavulanic Acid Series API Market Size Estimates and Forecasts
1.4.1 Global Clavulanic Acid Series API Revenue 2019-2030
1.4.2 Global Clavulanic Acid Series API Sales 2019-2030
1.4.3 Global Clavulanic Acid Series API Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Clavulanic Acid Series API Market Competition by Manufacturers
2.1 Global Clavulanic Acid Series API Sales Market Share by Manufacturers (2019-2024)
2.2 Global Clavulanic Acid Series API Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Clavulanic Acid Series API Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of Clavulanic Acid Series API, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Clavulanic Acid Series API, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Clavulanic Acid Series API, Product Type & Application
2.7 Global Key Manufacturers of Clavulanic Acid Series API, Date of Enter into This Industry
2.8 Global Clavulanic Acid Series API Market Competitive Situation and Trends
2.8.1 Global Clavulanic Acid Series API Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Clavulanic Acid Series API Players Market Share by Revenue
2.8.3 Global Clavulanic Acid Series API Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Clavulanic Acid Series API Market Scenario by Region
3.1 Global Clavulanic Acid Series API Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Clavulanic Acid Series API Sales by Region: 2019-2030
3.2.1 Global Clavulanic Acid Series API Sales by Region: 2019-2024
3.2.2 Global Clavulanic Acid Series API Sales by Region: 2025-2030
3.3 Global Clavulanic Acid Series API Revenue by Region: 2019-2030
3.3.1 Global Clavulanic Acid Series API Revenue by Region: 2019-2024
3.3.2 Global Clavulanic Acid Series API Revenue by Region: 2025-2030
3.4 North America Clavulanic Acid Series API Market Facts & Figures by Country
3.4.1 North America Clavulanic Acid Series API Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Clavulanic Acid Series API Sales by Country (2019-2030)
3.4.3 North America Clavulanic Acid Series API Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Clavulanic Acid Series API Market Facts & Figures by Country
3.5.1 Europe Clavulanic Acid Series API Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Clavulanic Acid Series API Sales by Country (2019-2030)
3.5.3 Europe Clavulanic Acid Series API Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Clavulanic Acid Series API Market Facts & Figures by Region
3.6.1 Asia Pacific Clavulanic Acid Series API Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Clavulanic Acid Series API Sales by Region (2019-2030)
3.6.3 Asia Pacific Clavulanic Acid Series API Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Clavulanic Acid Series API Market Facts & Figures by Country
3.7.1 Latin America Clavulanic Acid Series API Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Clavulanic Acid Series API Sales by Country (2019-2030)
3.7.3 Latin America Clavulanic Acid Series API Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Clavulanic Acid Series API Market Facts & Figures by Country
3.8.1 Middle East and Africa Clavulanic Acid Series API Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Clavulanic Acid Series API Sales by Country (2019-2030)
3.8.3 Middle East and Africa Clavulanic Acid Series API Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Clavulanic Acid Series API Sales by Type (2019-2030)
4.1.1 Global Clavulanic Acid Series API Sales by Type (2019-2024)
4.1.2 Global Clavulanic Acid Series API Sales by Type (2025-2030)
4.1.3 Global Clavulanic Acid Series API Sales Market Share by Type (2019-2030)
4.2 Global Clavulanic Acid Series API Revenue by Type (2019-2030)
4.2.1 Global Clavulanic Acid Series API Revenue by Type (2019-2024)
4.2.2 Global Clavulanic Acid Series API Revenue by Type (2025-2030)
4.2.3 Global Clavulanic Acid Series API Revenue Market Share by Type (2019-2030)
4.3 Global Clavulanic Acid Series API Price by Type (2019-2030)
5 Segment by Application
5.1 Global Clavulanic Acid Series API Sales by Application (2019-2030)
5.1.1 Global Clavulanic Acid Series API Sales by Application (2019-2024)
5.1.2 Global Clavulanic Acid Series API Sales by Application (2025-2030)
5.1.3 Global Clavulanic Acid Series API Sales Market Share by Application (2019-2030)
5.2 Global Clavulanic Acid Series API Revenue by Application (2019-2030)
5.2.1 Global Clavulanic Acid Series API Revenue by Application (2019-2024)
5.2.2 Global Clavulanic Acid Series API Revenue by Application (2025-2030)
5.2.3 Global Clavulanic Acid Series API Revenue Market Share by Application (2019-2030)
5.3 Global Clavulanic Acid Series API Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Wichita
6.1.1 Wichita Company Information
6.1.2 Wichita Description and Business Overview
6.1.3 Wichita Clavulanic Acid Series API Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Wichita Clavulanic Acid Series API Product Portfolio
6.1.5 Wichita Recent Developments/Updates
6.2 GSK
6.2.1 GSK Company Information
6.2.2 GSK Description and Business Overview
6.2.3 GSK Clavulanic Acid Series API Sales, Revenue and Gross Margin (2019-2024)
6.2.4 GSK Clavulanic Acid Series API Product Portfolio
6.2.5 GSK Recent Developments/Updates
6.3 Lek Pharmaceuticals (Sandoz)
6.3.1 Lek Pharmaceuticals (Sandoz) Company Information
6.3.2 Lek Pharmaceuticals (Sandoz) Description and Business Overview
6.3.3 Lek Pharmaceuticals (Sandoz) Clavulanic Acid Series API Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Lek Pharmaceuticals (Sandoz) Clavulanic Acid Series API Product Portfolio
6.3.5 Lek Pharmaceuticals (Sandoz) Recent Developments/Updates
6.4 CKD Bio Corporation
6.4.1 CKD Bio Corporation Company Information
6.4.2 CKD Bio Corporation Description and Business Overview
6.4.3 CKD Bio Corporation Clavulanic Acid Series API Sales, Revenue and Gross Margin (2019-2024)
6.4.4 CKD Bio Corporation Clavulanic Acid Series API Product Portfolio
6.4.5 CKD Bio Corporation Recent Developments/Updates
6.5 Zhuhai United Pharmaceutical
6.5.1 Zhuhai United Pharmaceutical Company Information
6.5.2 Zhuhai United Pharmaceutical Description and Business Overview
6.5.3 Zhuhai United Pharmaceutical Clavulanic Acid Series API Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Zhuhai United Pharmaceutical Clavulanic Acid Series API Product Portfolio
6.5.5 Zhuhai United Pharmaceutical Recent Developments/Updates
6.6 Shandong New Era Pharmaceutical
6.6.1 Shandong New Era Pharmaceutical Company Information
6.6.2 Shandong New Era Pharmaceutical Description and Business Overview
6.6.3 Shandong New Era Pharmaceutical Clavulanic Acid Series API Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Shandong New Era Pharmaceutical Clavulanic Acid Series API Product Portfolio
6.6.5 Shandong New Era Pharmaceutical Recent Developments/Updates
6.7 Sichuan Ren An Pharmaceutical
6.7.1 Sichuan Ren An Pharmaceutical Company Information
6.7.2 Sichuan Ren An Pharmaceutical Description and Business Overview
6.7.3 Sichuan Ren An Pharmaceutical Clavulanic Acid Series API Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Sichuan Ren An Pharmaceutical Clavulanic Acid Series API Product Portfolio
6.7.5 Sichuan Ren An Pharmaceutical Recent Developments/Updates
6.8 Fermic
6.8.1 Fermic Company Information
6.8.2 Fermic Description and Business Overview
6.8.3 Fermic Clavulanic Acid Series API Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Fermic Clavulanic Acid Series API Product Portfolio
6.8.5 Fermic Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Clavulanic Acid Series API Industry Chain Analysis
7.2 Clavulanic Acid Series API Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Clavulanic Acid Series API Production Mode & Process
7.4 Clavulanic Acid Series API Sales and Marketing
7.4.1 Clavulanic Acid Series API Sales Channels
7.4.2 Clavulanic Acid Series API Distributors
7.5 Clavulanic Acid Series API Customers
8 Clavulanic Acid Series API Market Dynamics
8.1 Clavulanic Acid Series API Industry Trends
8.2 Clavulanic Acid Series API Market Drivers
8.3 Clavulanic Acid Series API Market Challenges
8.4 Clavulanic Acid Series API Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Wichita
GSK
Lek Pharmaceuticals (Sandoz)
CKD Bio Corporation
Zhuhai United Pharmaceutical
Shandong New Era Pharmaceutical
Sichuan Ren An Pharmaceutical
Fermic

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂